Nuvo Research has reported that WF10, its immune modulating drug candidate, has met the primary endpoint a European Phase II clinical trial to evaluate it as a treatment for severe hayfever.

The placebo-controlled, randomised and double-blind trial was designed to evaluate the safety and efficacy of WF10.

The trial involved 60 patients who had at least a two-year history of persistent allergic rhinitis and who tested positive in a skin allergy test.

The drug successfully demonstrated a change in the total nasal symptom score from baseline to assessment after three weeks in the WF10 group when compared to the placebo group